| Next 10 |
Ad
ALXO Articles ALX Oncology Holdings Inc.
home / stock / alxo / alxo articles
Articles | ALX Oncology Holdings Inc. (NASDAQ:ALXO)
-
uniQure N.V. (NASDAQ: QURE) surged 76.5% on Jul 9 after it announced updated interim data, including up to 24 months of follow-up data, from 2...
-
Mesoblast Limited (NASDAQ: MESO) has witnessed a phenomenal run in the year so far. Shares of MESO have risen a whopping 208.2% year to date a...
-
Denali Therapeutics Inc. (NASDAQ: DNLI) is having a good run in 2024. Shares of this biopharmaceutical company have risen 11.9% in the past three m...
-
Roche (OTC: RHHBY) announced that the European Commission has granted marketing authorization to the subcutaneous formulation of relapsing mul...
-
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
-
Moderna, Inc. (NASDAQ: MRNA) announced that it has submitted an application to the FDA seeking approval of its Spikevax 2024-2025 formula, tar...
-
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
-
Intellia Therapeutics' (NASDAQ: NTLA) shares gained 10% on Jun 3 after the company reported encouraging long-term data from the phase I portion...
-
AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...
Stock Information
Get ALXO Alerts
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
-0.56% G/L:
$0.7419 Last:
505,520 Volume:
$0.788 Open:
$0.7419 Close:
ALX Oncology Holdings Inc. Website:
Ad
-
Air France-KLM ADR (AFLYY) is expected to report $0.02 for Q4 2024 Viracta Therapeutics Inc. (VIRX) is expected to report for Q4 2024 BJ's Wholesale Club Holdings Inc. (BJ) is expected to report $0.89 for Q4 2025 Deutsche Lufthansa AG ADR - Level I (DLAKY) is expected to report $0.22 ...
-
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients ...
-
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients ...